Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00829686 · ClinicalTrials.gov registry record · NA

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

A NA study, sponsored by 59th Medical Wing.

Completed
Registry status
NA
Development phase
31
Enrollment target

NCT00829686: Completed NA study, sponsored by 59th Medical Wing.

NCT00829686 is a NA study that has completed, run by 59th Medical Wing. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00829686, a NA study, has completed, sponsored by 59th Medical Wing.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target

Study Summary

Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1)no antibiotic or 2) bacterium double strength (DS) (800/160) two tablets per oral (PO) twice a day x 7 days. This is the dose recommended for treating skin and soft tissue infections. (Ellis et al. Current Opinion in Infectious Diseases. 18(6):496-501, December 2005) Patients will then return to the emergency room (ER) on days 3 and 7 for wound repacking and evaluation. The primary outcome is clinical cure of abscess at 7 days after incision and drainage and recurrence rates within 30 days of treatment. Patients who are not improving at the following visit will then be treated with additional antibiotics or admission if needed. Data will be analyzed both by initial randomization and intention to treat. This serves as the pilot for the full placebo controlled randomized trial.

Primary Outcome

improving wound without evidence of fever, worsening cellulitis or induration

Interventions

  • DRUG Septra

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2008-06
Est. Completion 2008-06
Phase NA
59th Medical Wing

20 total trials

What the finished NCT00829686 record still lists

NCT00829686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Septra is the first listed.

NCT00829686 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00829686 about?

NCT00829686 is a clinical study titled "Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection". Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1)no antibiotic or 2) bacterium double strength (DS) (800/160...

What is the current status of trial NCT00829686?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-06. Estimated completion is 2008-06.

What interventions are being tested in trial NCT00829686?

The interventions under investigation include: Septra (DRUG).

Who is sponsoring clinical trial NCT00829686?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00829686's enrollment target sits among peer trials

31 1592nd of 2000 higher than 408 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00829686, the US trial registry maintained by the National Library of Medicine. NCT00829686 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.